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Abstract
An important feature of COVID-19, the disease produced
by the new coronavirus SARS-CoV-2, is the high number of
health care workers (HCWs) that acquire the disease. In an
initial report of 138 patients hospitalized with COVID-19 pneumonia in China, 40 patients (29%) were HCWs. One reason
why HCWs are at higher risk of acquiring COVID-19 is that
some patients with COVID-19 are admitted to the hospital
without the classical presentation and are therefore not tested
for the disease early during hospitalization. Presently in the
US, it is recommended to test for COVID-19 when physicians
suspect the disease. This subjective approach may allow hospital transmission of COVID-19 from patients without the classical clinical presentation. The primary objective of this study
is to establish a surveillance system for early identification of
patients hospitalized with COVID-19 to allow for early imple-

mentation of infection control interventions in an attempt to
prevent transmission of COVID-19 to HCWs and other hospitalized patients. We are proposing to test all patients who
present to the emergency departments and/or are hospitalized with signs and symptoms of respiratory infection or gastrointestinal infection for SARS-CoV-2, regardless of clinical
suspicion of COVID-19. Biological samples obtained from
all patients having symptoms of respiratory or gastrointestinal
infection will be tested using real-time reverse transcriptasepolymerase chain reaction (RT-PCR) for detection of SARSCoV-2. Using a robotic instrument, the CMP laboratory will
be able to test more than 500 samples a day. Data will be
reported in real-time to participating hospitals for rapid implementation of infection control measures.

Introduction and Rationale

with COVID-19 pneumonia in China, 40 patients (29%)
were HCWs.[1] One reason why HCWs are at higher
risk of acquiring COVID-19 is because some patients
with COVID-19 are admitted to the hospital without
the classical presentation, and are therefore not tested
for the disease early during hospitalization. Wang et
al. reported one patient admitted to the surgical ward
complaining of fever, abdominal pain, and diarrhea.
This patient infected 10 HCWs from the surgical department.[1] The concern with the current surveillance
system is that patients are tested only when clinicians
suspect the disease. Patients are suspected to have
COVID-19 when they present with a syndrome of respiratory infection associated with pneumonia or respiratory failure. Early manifestations of COVID-19 may
include a syndrome of upper respiratory tract infection,
a flu-like syndrome, or a gastrointestinal syndrome
presenting with diarrhea (Figure 1).[2]

The reliability of the healthcare system is a critical
component in the fight against new pandemics. To
have an effective healthcare infrastructure, it is critical
to have a healthy healthcare workforce. The healthcare workforce encompasses a wide range of professions and occupations who provide any type of healthcare service, such as physicians, nurses, surgeons, dentists, physical and behavior therapists, as well as allied health professionals such as respiratory therapists,
phlebotomists, medical laboratory scientists, dieticians,
and social workers.
An important feature of COVID-19, the disease produced by the new coronavirus SARS-CoV-2, is the high
number of health care workers (HCWs) that acquire the
disease. In an initial report of 138 patients hospitalized
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Figure 1. Spectrum of disease of patients with COVID-19 (adapted from reference 2).

In the Louisville Coronavirus Surveillance Program,
we are proposing to remove the subjective nature of
testing and instead test for SARS-CoV-2 all patients in
the emergency department with signs and symptoms
of respiratory infection or gastrointestinal infection, regardless of clinical suspicion of COVID-19. Some of
these patients will be hospitalized and others will be
discharged home. Some patients are hospitalized as a
direct admission from ambulatory settings. These patients will be tested in the patient care area after they
are hospitalized. We are proposing the implementation
of this testing in all hospitals in the city of Louisville as
part of a comprehensive SARS-CoV-2 surveillance program.
It is also important to address the concern that HCWs
may be afraid to come to work where there is documented hospital transmission of COVID-19. By having an active surveillance system, it is reasonable to assume that this knowledge may serve to make HCWs
feel safer than the unknown that is present without this
level of comprehensive surveillance. Further, this organized approach may serve to minimize unnecessary
use of hospital resources such as personal protective
equipment (PPE) as part of incremental testing, as opposed to testing done through a standardized surveillance process.
The information gained through this surveillance system will be used to generate guidelines for real-time
hospital and community education and response activities. Additionally, data obtained as part of this surveillance will be used to produce educational components
for a wide range of audiences, including daily multimedia announcements that will keep the community

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/3

up to date on local and reliable COVID-19 information. The lessons learned from this program will be immediately transferred to manuscript for submission to
peer-reviewed publications with the goal of rapid dissemination of the knowledge gained from this project.
The information will also be shared community-wide
through select University of Louisville digital channels.

Objectives
Primary objectives
1. To establish a new surveillance system for early
identification of hospitalized patients with COVID19.
2. To prevent transmission of COVID-19 to health care
workers and other hospitalized patients.
Secondary objectives
1. To strengthen existing systems of surveillance for
COVID-19.
2. To better inform Public Health authorities of local
COVID-19 activity.
3. To define areas of the community where surveillance
activities should be increased.
4. To identify cases of COVID-19 from emergency departments among patients who may not be hospitalized.
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Figure 2. The four components of the program with the primary activities for each component.

5. To generate educational components and guidelines
for real-time hospital and community education and
response activities.
6. To rapidly disseminate the new knowledge gained
by this project.
An overview of the different components of this project
with the most relevant activities for each component is
depicted in Figure 2.

Study Design
Program Overview
This proposal is a collaboration of 1) the Center of Excellence for Research in Infectious Diseases (CERID),
University of Louisville, 2) the Center for Predictive
Medicine for Biodefense and Emerging Infectious Diseases (CPM), University of Louisville, 3) all hospitals
in the city of Louisville, and 4) the Louisville Metro Department of Public Health and Wellness. An overview
of the program is depicted in Figure 3.
On February 12, 2020 the University of Louisville Regional Biocontainment Laboratory received an isolate
of the SARS-CoV-2 from the CDC. Investigators from
the CPM cultured the virus and started to work on
the development of real-time polymerase chain reaction (RT-PCR).
Patients with signs and symptoms of respiratory or
gastrointestinal infection seen in one of the ten emergency departments will be included in the surveillance
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process. Hospitalized patients directly admitted to the
hospital will also be included. Samples will be collected
as soon as possible and transferred to the CPM laboratory for testing. Three databases will be developed to
store project data. Clinical and epidemiological data
will be collected by the surveillance team and maintained in a REDCap database specifically designed for
this purpose. Specimen collected will be retained in a
biorepository for future testing and a REDCap database
will be designed for this purpose. Data from the CPM
laboratory will be collected and maintained in a REDCap database specifically designed for this purpose.
All three of these REDCap databases will comprise the
Comprehensive Surveillance Database for this COVID19 surveillance program, and will be accessible in realtime with secure passwords to all participating institutions, public health authorities, and other stakeholders.
Program Advisory Board
An advisory board will be established with the following objectives: 1) To maintain open and consistent communication related to the original status of COVID-19
disease; 2) To provide feedback for improvement of the
surveillance program; and 3) To support the dissemination of information. In addition to public health and
other relevant stakeholders, the advisory board members may include representation from hospital emergency, infection control, nursing, medical staff, and
administration departments. Project investigators and
members of the advisory board will hold regular meetings to align the course of the project with the COVID19 epidemic.
Preliminary Studies
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Figure 3. Overview of the Louisville Coronavirus Surveillance Program.

The two principal investigators, Drs. Julio Ramirez and
Kenneth Palmer, have vast experience in development
and implementation of these types of projects.
Dr. Ramirez is the Chief of the Division of Infectious Diseases and Director of the Center of Excellence
for Research in Infectious Diseases (ceridlouisville.org).
He has led multiple surveillance programs in the State
of Kentucky, including the Severe Influenza Pneumonia Surveillance (SIPS) Project. SIPS was funded by
the Department of Homeland Security.[3] He was also
funded by the Centers for Disease Control and Prevention to study the role of oseltamivir in hospitalized patients with influenza in the city of Louisville. This was
done in collaboration of CERID with all adult hospitals in Louisville.[4] More recently, Pfizer Pharmaceuticals sponsored CERID to perform a population-based
study of all hospitalized adult patients in the city of
Louisville to define the burden of community-acquired
pneumonia. Data from this study was used to estimate
burden of pneumonia in the United States.[5] The successes of these studies led to the selection of CERID as
the North American Center of Excellence for Vaccine
Epidemiology, funded by Pfizer. This is the first such
center in the world, and recognizes the unique infrastructure and capabilities of UofL CERID (Center of Excellence announcement).
Dr. Kenneth Palmer is the Director of the Center for
Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM), and Professor of Pharmacology and Toxicology. He was trained as a virologist at
the University of Cape Town, and his research program
has focused on development of biologic-based antivirals and vaccines. Q-Griffithsin (Q-GRFT) is a broad-
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spectrum antiviral protein that was discovered and developed in Dr. Palmer’s laboratory. Q-GRFT has been
formulated for rectal administration and Dr. Palmer
leads an NIH-funded translational research program
that is testing the product safety in a first-in-humans
clinical trial for HIV-1 prevention.[6-8] Dr. Palmer
has also worked as part of teams that have demonstrated Q-GRFT activity against a broad array of Coronaviruses, including SARS-CoV and MERS-CoV. Dr.
Palmer is leading a team of researchers that are now
working on developing in vitro and in vivo systems for
assessing SARS-CoV-2/COVID-19 antiviral and vaccine strategies.
The CV of the two principal investigators are included
in Appendices 2 and 3.
Laboratory Methods
Since one of the goals of this study is to define if
SARS-CoV-2 is present in different biological samples,
specimens regularly collected as part of standard of
care clinical practice (e.g., respiratory, blood, stool, and
urine specimen) will be obtained as they are available.
The specimen will be transferred from the local hospital to the CERID Biorepository Laboratory for labeling
and cataloging. Each specimen will be labeled with a
Patient Sample ID to maintain privacy, while also allowing real-time reporting to a specific hospital. Specimen are transported from the CERID Biorepository Lab
to the CPM Laboratory for testing.
The CPM laboratory will use the specimen for RNA
extraction. This will involve use of two commercial
RNA isolation platforms for performance assessment.
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Figure 4. Structure of the project coordinating center.

CPM will also assess two different quantitative reverse transcriptase PCR platforms for SARS-CoV-2 detection. Once CPM has validated the test outcomes
with spiked samples, they will chose a single RNA isolation platform and qRT-PCR platform for the surveillance project.
CPM will collect qPCR data, provide an analytical report, and enter the data into the laboratory database.
Program Coordinating Center
The study will be coordinated by Center of Excellence
for Research in Infectious Diseases (CERID). The current structure of CERID is depicted in Figure 4.
The activities related to this project for each of the
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CERID units are as follows:
Data Management Unit: generate the data collection
form and the three REDCap databases, clinical, epidemiological, and laboratory, for this project.
Implementation Unit: responsible for all surveillance
activities, transport of the specimen to the CPM laboratory, data collection, and data entry into the REDCap
databases.
Laboratory Unit: catalog all clinical samples and coordinate with the CPM laboratory for testing.
Biorepository Unit: will be responsible for maintaining all specimen for future testing and entering data
into the biorepository database.
5
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Quality Assurance Unit: will be responsible for monitoring data quality and ongoing process improvement.
Biostatistics Unit: will be responsible for periodic and
real-time analysis of clinical, epidemiological, and laboratory data.
Medical Writing Unit: will support the generation of
manuscripts.
Peer-Review Journals Unit will facilitate rapid publication of new knowledge.
Informatics Unit: will interface the three databases
and generate real-time reports with de-identified information about local COVID-19 activity.
Community Outreach Unit: will be responsible for
maintaining open lines of communication with community leaders and coordinating activities of the Advisory Board.
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University Outreach Unit: will be responsible for
maintaining open lines of communication with UofL
leaders and will work with the Community Outreach
Unit to coordinate the activities of the Advisory Board.
Marketing Unit: will collaborate with investigators to
develop education and response communications.
Protection of Human Participants
All patient information will be entered into REDCap
databases, which are HIPAA-compliant. All surveillance information is considered protected health information and standard data safety processes will be followed.
Letters of Support
Please see Appendix 4.
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